Blog
Published December 7, 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to consider the latest challenges and opportunities being addressed by health economics and outcomes research. Topics included Joint Clinical Assessments (JCAs), access to innovative therapies, environmental…
Read Now
Blog
Published November 17, 2023
Introduction
The Trinity team recently attended the Milken Institute’s 2023 Future of Health Summit in Washington, DC. Its theme was “Closing the Gap” in healthcare – as chronic disease becomes more prevalent worldwide and the average life expectancy in the US declines to its lowest level since the early 1990’s, what can be done? The sessions explored how industry leaders, government officials, nonprofits, and patients can work together to reverse the declining and diverging metrics we see in healthcare outcomes…
Read Now
Scientific Publications
Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe
Acosta Luis S1, O’Hara M2, Yeh M2
1Trinity Partners, LLC, London, UK, 2Trinity Life Sciences, Waltham, MA, USA
The EU-wide Joint Clinical Assessment (JCA) is set to be operational from January 2025. The Trinity team reviewed the available literature and summarized the JCA implications for medical device launch planning and evidence-generation requirements, including the central role that HEOR expertise across different geographies will…
Read Now
Blog
Published November 7, 2023
In August 2023, the Colombian government published a new pricing policy outlining that the list price of new medicines in Colombia will be established based on their therapeutic value category, resulting from an assessment conducted by the Instituto de Evaluation Tecnológica en Salud (IETS). The outcomes of the therapeutic assessment are then reported to the National Commission for Prices of Medicines and Medical Devices (CNPMDM), which is responsible for setting the list price of the new drugs. Up until now,…
Read Now
Webinars
Available On Demand
Watched our AIML 101 webinar and ready to learn more? Trinity Life Sciences is excited to continue the conversation with our next webinar, which will dive deeper into how pharma companies can move beyond the hype to unlock the value of Generative AI (GenAI).
Join Trinity experts, Steve Laux, VP of Commercial Insights & Advanced Analytics, Nabha Subramanya, VP of Data Science and Patrick Waring, Director of New Products & Strategy, as they sift through all the noise surrounding GenAI and share…
Watch Now
Webinars
Available On Demand
Join Leslie Orne, President and CEO at Trinity Life Sciences, as she discusses how Trinity is helping life sciences companies launch in Europe at the Jefferies London Healthcare Conference.
Key Topics:
Trinity’s data-driven and insight-driven approach to support clients across their commercial journey.
Trinity’s expertise in helping clients plan market access, evaluate strategic options, develop a shortlist of partners and optimize their approach.
How Trinity’s local team in Europe can bring in-depth expertise, local language, regulatory experience and in-market experience…
Watch Now
White Papers
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms of P&MA strategies.
China’s aging population (≥60 years) is estimated to exceed 400 million by 2035 driving a significant rise in government healthcare expenditure and medical insurance subsidies in the future. As such, the Chinese government has acknowledged the important…
Read Now
Webinars
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to…
Watch Now
Briefs
Rare diseases present unique challenges to companies looking to commercialize treatments.
Although there is vast potential in rare disease, each space is different and unique.
Companies must effectively address challenges around identifying and treating patients—as well as providing long-term support. It is critical that companies understand the nuances in each disease.
Keeping a patient-first mentality, advancing patients’ needs and providing excellent support services are mission-critical for life sciences companies touching rare disease. However, lack of disease awareness and unclear referral…
Read Now
Blog
Published October 12, 2023
Recently Trinity Life Sciences’ team members had the opportunity to attend the Intellus Worldwide Institute in Boston. The institute featured interactive discussions about topics impacting health insights and analytics, including the evolving payer landscape, increasing importance of patient segmentation and growing role of AI in healthcare.
Evolving Payer Research Landscape
Discussions about the payer research landscape centered on the importance of increasing the visibility of payer insights across research phases and brand verticals, especially in light of greater cost consciousness. …
Read Now
